Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications

Russo, Vincenzo; Rago, Anna; Carbone, Andreina; Bottino, Roberta; Ammendola, Ernesto; Cioppa, Nadia Della; Galante, Dario; Golino, Paolo; Nigro, Gerardo

doi:10.1097/fjc.0000000000000854

Cited by 41 publications

(34 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Atrial fibrillation was the most common cardiac arrhythmia observed in patients with COVID-19 infection according to one survey [27]. The mechanisms that might cause atrial fibrillation in these patients are possibly due to systemic infection, direct viral cardiomyocyte injury, hypoxemia, and susceptibility of the population due to advanced age and their comorbidities, and, finally, sympathetic nervous system overactivity [28].…”

Section: Arrhythmias In Covid-19mentioning

confidence: 99%

Arrhythmia in COVID-19

Babapoor-Farrokhran

Rasekhi

Gill

et al. 2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The current outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) also known as coronavirus disease 2019 (COVID-19) has quickly progressed to a global pandemic. There are well-documented cardiac complications of COVID-19 in patients with and without prior cardiovascular disease. The cardiac complications include myocarditis, heart failure, and acute coronary syndrome resulting from coronary artery thrombosis or SARS-CoV-2-related plaque ruptures. There is growing evidence showing that arrhythmias are also one of the major complications. Myocardial inflammation caused by viral infection leads to electrophysiological and structural remodeling as a possible mechanism for arrhythmia. This could also be the mechanism through which SARS-CoV-2 leads to different arrhythmias. In this review article, we discuss arrhythmia manifestations in COVID-19.

show abstract

Section: Arrhythmias In Covid-19mentioning

confidence: 99%

Arrhythmia in COVID-19

Babapoor-Farrokhran

Rasekhi

Gill

et al. 2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

show abstract

“…A recent Italian multicenter observational study showed a prevalence of 12.5% among hospitalized COVID-19 patients [29]; moreover, a report by the COVID-19 Task Force of the Italian National Institute of Health showed that 22.5% of non-surviving COVID-19 patients (n: 355, mean age 79.5 years, 30% women) presented atrial fibrillation as comorbidity diagnosed before the SARS-CoV-2 infection [50]. The approach to atrial fibrillation (AF) management should take into consideration several pharmacological interactions between antiarrhythmic and experimental COVID-19 therapies [51] Ventricular arrhythmias seem to be directly correlated to COVID-19 induced myocardial injury Among a cohort of 187 COVID-19 patients without history of arrhythmias, the subjects with elevated TnT levels more frequently developed malignant arrhythmias, including ventricular tachycardia and fibrillation during hospitalization (2 (1.5%) vs. 9 (17.3%) compared to those with normal TnT levels [52].…”

Section: Arrhythmiasmentioning

confidence: 99%

Section: Arrhythmiasmentioning

confidence: 99%

COVID-19 and Heart: From Clinical Features to Pharmacological Implications

Russo

Bottino

Carbone

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

A highly pathogenic human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized in Wuhan, China, as the cause of the coronavirus disease 2019 (COVID-19) outbreak which has spread rapidly from China to other countries in the world, causing a pandemic with alarming morbidity and mortality. The emerging epidemiological data about COVID-19 patients suggest an association between cardiovascular diseases (CVD) and SARS-CoV-2 infection, in term of clinical features at hospital admission and prognosis for disease severity. The aim of our review is to describe the cardiological features of COVID-19 patients at admission, the acute cardiac presentation, the clinical outcome for patients with underlying CVD and the pharmacological implications for disease management.

show abstract

“…Also, severe hypoxemia, as the ultimate pathophysiological cause of death, is detected both in heart failure and COVID-19 patients [11]. COVID-19related hypoxemia may also possibly induce atrial fibrillation as the most common arrhythmia among hospitalized individuals [13]. Atrial fibrillation is life-threatening if it becomes refractory and runs into a detrimental cycle, especially before respiratory function returns to a normal status.…”

Section: Cardiovascular System Vulnerability and Covid-19: An Emerginmentioning

confidence: 99%

Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure

Razeghian‐Jahromi

Zibaeenezhad

et al. 2020

Heart Fail Rev

View full text Add to dashboard Cite

The coronavirus disease (COVID-19) pandemic is a global health priority. Given that cardiovascular diseases (CVD) are the leading cause of morbidity around the world and that several trials have reported severe cardiovascular damage in patients infected with SARS-CoV-2, a substantial number of COVID-19 patients with underlying cardiovascular diseases need to continue their medications in order to improve myocardial contractility and to prevent the onset of major adverse cardiovascular events (MACEs), including heart failure. Some of the current life-saving medications may actually simultaneously expose patients to a higher risk of severe COVID-19. Angiotensinconverting enzyme 2 (ACE2), a key counter regulator of the renin-angiotensin system (RAS), is the main entry gate of SARS-CoV-2 into human host cells and an established drug target to prevent heart failure. In fact, ACE inhibitors, angiotensin II receptor blockers, and mineralocorticoid antagonists may augment ACE2 levels to protect organs from angiotensin II overload. Elevated ACE2 expression on the host cell surface might facilitate viral entrance, at the same time sudden nonadherence to these medications triggers MACEs. Hence, safety issues in the use of RAS inhibitors in COVID-19 patients with cardiac dysfunction remain an unsolved dilemma and need paramount attention. Although ACE2 generally plays an adaptive role in both healthy subjects and patients with systolic and/or diastolic dysfunction, we conducted a literature appraisal on its maladaptive role. Understanding the exact role of ACE2 in COVID-19 patients at risk of heart failure is needed to safely manage RAS inhibitors in frail and non-frail critically ill patients.

show abstract

Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications

Cited by 41 publications

References 34 publications

Arrhythmia in COVID-19

Arrhythmia in COVID-19

COVID-19 and Heart: From Clinical Features to Pharmacological Implications

Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure

Contact Info

Product

Resources

About